Clincosm LogoSign in Get a demo

Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients With Non-segmental Vitiligo

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05121532
Collaborator
(none)
60
Enrollment
2
Arms
11
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients with Non-segmental Vitiligo before and after phototherapy

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Interleukin-15 and Interleukin-22
 N/A

Detailed Description

This prospective study will include 30 patients with NSV, attending the Outpatient Clinics of Dermatology at Sohag University Hospitals, as well as 30 normal volunteers as control.

This study will be submitted for approval by Research and Ethical committees at Sohag Faculty of Medicine. An informed written consent will be obtained from each subject prior to participation in the study after full explanation of the procedure.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients With Non-segmental Vitiligo
Anticipated Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: non segmental vitiligo

serum analysis

Diagnostic Test: Interleukin-15 and Interleukin-22
Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo
Active Comparator: normal volunteer

serum analysis

Diagnostic Test: Interleukin-15 and Interleukin-22
Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo

Outcome Measures

Primary Outcome Measures

  1. Evaluation of Serum Interleukin-15 and Interleukin-22 Levels [3 months]

    3 ml venous blood will be obtained from participante using commerciall available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kits to evaluate Serum IL15 level . Serum IL22 level. 3 ml venous blood will be obtained from participante using commerciall available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kits to evaluate 1. Serum IL15 level . 2. Serum IL22 level.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • • Patients suffering from non segmental vitiligo.

  • Patients not on medical treatment or phototherapy for vitiligo in the last 3 months.

Exclusion Criteria:

  • • Patients with systemic or cutaneous inflammatory disorders.

  • Patients on treatment for vitiligo in last 3 months.

  • Pregnant and lactating patients.

  • Patients with history of diabetes.

  • Patients with history of autoimmune diseases.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Samah Saeed Badrous, resident doctor at dermatology department balina central hospital, Sohag University
ClinicalTrials.gov Identifier:
NCT05121532
Other Study ID Numbers:
  • Soh-Med-21-11-12
First Posted:
Nov 16, 2021
Last Update Posted:
Nov 16, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Vitiligo

Study Results

No Results Posted as of Nov 16, 2021